EDESA BIOTECH, INC. Business Acquisition, Pro Forma Net Income (Loss)
EDESA BIOTECH, INC. (EDSA) reported Business Acquisition, Pro Forma Net Income (Loss) of -$8.13 million for the 9-month period ending 2019-09-30, per its 10-K filed 2020-12-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2020-12-07
- EDESA BIOTECH, INC. business acquisition, pro forma net income (loss) for fiscal 2018 was -$6.58M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|
| 2019-09-30 | -$8.13M 10-K · filed 2020-12-07 | |
| 2018-12-31 | -$6.58M 10-KT · filed 2019-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |